You are now leaving the United Therapeutics ASSIST website and moving to an external website independently operated and not managed by United Therapeutics, Inc.
If you do not wish to leave this site, click Cancel. Or click OK to continue.
*Indicates required field.
**Phone number is required because patient consent may be necessary for certain topics of communication.
This Form is NOT intended to contact United Therapeutics Corporation’s Medical Information Department or to report suspected Adverse Events. In the event of either, please use the contact information below.
Medical Information: Call 1-877-522-2950 or send requests directly to: DrugInformation@unither.com. Adverse Events: To report a suspected adverse reaction (ADR) to United Therapeutics, please send ADR information to DrugSafety@unither.com, or by faxing the ADR information to 1-919-313-1297, or to report ADRs to the FDA, ADR information can be submitted at 1-800-FDA-1088 or www.fda.gov/medwatch.
Thank you for your interest.
We will be in contact with you soon in regard to this inquiry.
Prior Authorization Checklist
Download
Sample Statement of Medical Necessity
Sample Appeal Letter
Patient Authorization Form
Updated: 11/13/2023
Patient Authorization Form - Spanish
Updated: 03/21/2024
If not, check The United Therapeutics Resource Library.
Remodulin is a prescription medication used to treat adults with pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. Remodulin can reduce symptoms associated with exercise. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. It is not known if Remodulin is safe and effective in children.
In people with PAH who need to switch from epoprostenol, Remodulin is approved to slow the worsening of symptoms.
Important Safety Information for Remodulin
Before you take Remodulin, tell your healthcare provider if you:
What are the serious side effects of Remodulin?
What are the possible side effects of Remodulin?
For more information about REMODULIN, please visit www.remodulin.com